Studying asparaginase side effects in leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how a common chemotherapy drug called asparaginase affects people in real life. It aims to understand side effects better so doctors can improve care for patients with leukemia or lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia.
- You must be enrolled in the INITIALL study at St. Jude.
- You must be within 10 days of starting your post-INITIALL treatment.
- Your post-INITIALL treatment must be either standard of care (as per Total therapy) or the SJALL23T plan without venetoclax (a type of targeted therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (DNA) differences to understand acute lymphoblastic leukemia (ALL) in Indian children and how treatments may fit better. You may be able to join if your child is newly diagnosed, meets the study’s treatment plan rules, and provides consent.
This study looks at why some patients have allergic reactions to asparaginase, a chemotherapy drug used to treat acute lymphoblastic leukemia. By studying blood samples taken before the consolidation phase, researchers hope to find ways to predict and manage these reactions.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
This study looks at how the immune system (T cells and B cells) responds to a common chemotherapy drug called asparaginase. It aims to understand why some children develop antibodies against the drug, which may cause allergic reactions and reduce effectiveness, to help improve future treatments.
This trial looks at how a medicine called asparaginase affects blood clotting in children treated for acute lymphoblastic leukaemia (a type of blood cancer). It may help doctors better manage bleeding or clot risks during treatment.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
Hear when a new Drug Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.